Across TCGA pan-cancer cohorts, NPIPB5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NPIPB5 data layer compared with 28 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher NPIPB5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPIPB5 expression acts as an unfavorable survival marker.
OV are the cancer types where NPIPB5 Mutation most reproducibly stratifies survival.